Atrophic vaginitis is a condition that occurs due to a decrease in estrogen levels in postmenopausal women. It results in thinning, drying and inflammation of the vaginal walls. Common symptoms include vaginal dryness, itching, burning sensation and pain during sexual intercourse. Treatment options for atrophic vaginitis include topical estrogen therapy in the form of creams, tablets and rings. Other alternatives include moisturizers and lubricants.
The global atrophic vaginitis treatment market is estimated to be valued at US$ 658.33 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Rising prevalence of atrophic vaginitis due to increasing menopausal population is a major factor driving the growth of this market. According to the United Nations, the global population of women aged 50 years and older is projected to grow from 962 million in 2017 to 1.3 billion by 2030. Growth in postmenopausal population subsequently raises the risk of developing atrophic vaginitis worldwide. Additionally, commercial availability of new treatment formulations such as vaginal rings and moisturizers is also boosting the demand for atrophic vaginitis treatment. For instance, in December 2021, TherapeuticsMD Inc. launched the BIJUVA 1mg/100 mcg vaginal tablets for the treatment of moderate to severe vasomotor symptoms due to menopause. This new treatment reduces vaginal pH and provides relief from atrophic vaginitis symptoms for women.
SWOT Analysis
Strength: Atrophic vaginitis causes discomfort that negatively impacts quality of life, so there is significant demand for effective treatment options. Estrogen-based therapies can effectively relieve symptoms like dryness and pain when applied topically in a safe, convenient form such as a cream or ring. Innovation in drug delivery technology may improve adherence to maintenance regimens.
Weakness: Topical estrogen therapies carry a black box warning due to potential risks like endometrial cancer and breast cancer with long-term use. This can reduce patient willingness to try these first-line options or persist with maintenance therapy. Non-hormonal alternatives currently lack the efficacy of estrogen.
Opportunity: There is an opportunity to develop new treatment modalities that provide the symptom relief of estrogen without the safety concerns, such as tissue selective estrogen complex formulations or other novel mechanisms of action. Expanding access to convenient prescription and over-the-counter options could also address barriers to treatment.
Threats: Increasing awareness of risks may reduce the eligible patient population and increase pressure for non-estrogen alternatives, intensifying competition. Biosimilars pose a cost containment threat once branded products lose exclusivity. Regulatory hurdles remain for over-the-counter switch of existing prescription products.
Key Takeaways
The global Atrophic Vaginitis Treatment market is expected to witness high growth over the forecast period of 2023 to 2030. The North American region currently dominates due to advanced healthcare infrastructure and favorable reimbursement policies. However, rising awareness and access to diagnosis and treatment in underpenetrated emerging markets will likely drive higher growth rates in other regions going forward.
Key players operating in the atrophic vaginitis treatment market are Pfizer Inc., TherapeuticsMD Inc., Allergan plc (AbbVie Inc.), Duchesnay USA, Novo Nordisk A/S, Merck & Co., Inc., Endoceutics Inc., Bausch Health Companies Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd. These companies hold a major share of the market and are focused on expanding indications and developing new products to sustain leadership positions amid increasing competition.
The North American region currently accounts for a sizable portion of the global atrophic vaginitis treatment market share due to advanced healthcare systems and supportive reimbursement programs. Europe also has a significant presence. However, the Asia Pacific region is expected to witness the fastest growth over the forecast period given its vast population, improving access to diagnosis and care, and large patient pools made vulnerable by lifestyle changes and aging trends in regional powerhouses like China and India.
Get More Insights Here
https://www.articlebowl.com/the-global-automotive-floor-mats-market-is-estimated-to-propelled
